Tristel are thrilled to announce the appointment of our new CEO, Matt Sassone, effective from 2 September 2024.
- With over 27 years of experience in the medical industry, Matt brings invaluable expertise to our team.
- His deep understanding of the US healthcare market will be crucial as we continue to expand our presence.
- Matt joins us from Masimo Corporation, a leading global medical technology company in the US.
- His impressive career also includes significant roles at Maquet, ArjoHuntleigh, and Smiths Medical.
- He holds a degree in biochemistry with microbiology, further strengthening our scientific foundation.
Our Founder and outgoing CEO, Paul Swinney, shared his enthusiasm about this transition:
“I am excited to hand the reins of this marvellous company to Matt. We have become the global market leader in manual high-level disinfection of medical devices and now have a foothold in the world’s largest healthcare market. Matt’s first-hand experience of North America will propel us to great success there. In our time on AIM, we have succeeded in increasing our share price by almost 12 times and have returned over 75 pence per share in dividends to our shareholders. I think we have created a great UK success story.”
We believe that under Matt’s leadership, Tristel will continue to achieve remarkable milestones and drive innovation in infection control.
Read in Full: Press Release – Directorate Changes 10 June 2024